Penumbra, Inc. (NYSE:PEN) Shares Acquired by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC raised its stake in Penumbra, Inc. (NYSE:PENFree Report) by 10.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 5,251 shares of the company’s stock after acquiring an additional 481 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Penumbra were worth $1,270,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Hollencrest Capital Management purchased a new position in shares of Penumbra during the second quarter worth approximately $25,000. Captrust Financial Advisors grew its position in shares of Penumbra by 44.1% during the second quarter. Captrust Financial Advisors now owns 219 shares of the company’s stock worth $27,000 after acquiring an additional 67 shares during the last quarter. Altshuler Shaham Ltd purchased a new position in shares of Penumbra during the fourth quarter worth approximately $27,000. Pinebridge Investments L.P. purchased a new position in Penumbra in the 2nd quarter valued at $30,000. Finally, Optimum Investment Advisors purchased a new position in Penumbra in the 2nd quarter valued at $34,000. 88.18% of the stock is currently owned by hedge funds and other institutional investors.

Penumbra Trading Up 0.3 %

Penumbra stock opened at $273.04 on Friday. The stock has a market cap of $10.54 billion, a PE ratio of 265.09 and a beta of 0.54. The stock has a 50-day moving average price of $248.79 and a 200 day moving average price of $242.46. Penumbra, Inc. has a 52 week low of $180.93 and a 52 week high of $348.67. The company has a current ratio of 5.99, a quick ratio of 3.41 and a debt-to-equity ratio of 0.02.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on PEN shares. Piper Sandler reduced their target price on Penumbra from $335.00 to $250.00 and set an “overweight” rating for the company in a report on Friday, November 3rd. Truist Financial raised their target price on Penumbra from $265.00 to $295.00 and gave the company a “buy” rating in a report on Friday, December 22nd. TheStreet raised Penumbra from a “d+” rating to a “c-” rating in a report on Friday, January 12th. Morgan Stanley reduced their target price on Penumbra from $265.00 to $240.00 and set an “equal weight” rating for the company in a report on Friday, November 3rd. Finally, Royal Bank of Canada raised their target price on Penumbra from $248.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, January 11th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Penumbra presently has a consensus rating of “Moderate Buy” and a consensus target price of $307.25.

Get Our Latest Research Report on PEN

Insider Buying and Selling

In related news, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $214.14, for a total transaction of $128,484.00. Following the completion of the sale, the executive vice president now owns 63,037 shares in the company, valued at approximately $13,498,743.18. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Bridget O’rourke sold 150 shares of Penumbra stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $226.41, for a total transaction of $33,961.50. Following the completion of the sale, the director now owns 4,214 shares in the company, valued at approximately $954,091.74. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $214.14, for a total value of $128,484.00. Following the sale, the executive vice president now owns 63,037 shares of the company’s stock, valued at approximately $13,498,743.18. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,435 shares of company stock worth $319,350. 5.30% of the stock is owned by corporate insiders.

Penumbra Company Profile

(Free Report)

Penumbra, Inc, together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands.

Featured Articles

Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PENFree Report).

Institutional Ownership by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.